What is XBIT's current stock price?

XBIT (XBiotech Inc.) is currently trading at $2.43 with a market cap of $74.1M.

What sector is XBiotech Inc. in?

XBiotech Inc. (XBIT) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

XBIT XBiotech Inc.

Healthcare

$2.43-2.02%ClosedMarket Cap: $74.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.55

P/S

0.00

EV/EBITDA

1.06

DCF Value

$4.08

FCF Yield

-57.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-26.1%

ROA

-28.7%

ROIC

-35.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-5.5M	$—
Q4 null	$0.00	$-26.9M	$—
FY null	$0.00	$-45.5M	$—
Q3 null	$0.00	$-6.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Troy Tevi Daviddirector

SellWed Nov 12

Soffer David Spencerdirector

SellWed Nov 12

Rademaker Craig Evandirector

SellWed Nov 12

Kuendig Thomas Martindirector

SellWed Nov 12

Soffer David Spencer

SellTue Sep 30

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.86

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Peers